Curi RMB Capital LLC Lowers Position in Catalent, Inc. (NYSE:CTLT)

Curi RMB Capital LLC lessened its stake in Catalent, Inc. (NYSE:CTLT) by 23.5% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,590 shares of the company’s stock after selling 29,662 shares during the quarter. Curi RMB Capital LLC owned approximately 0.05% of Catalent worth $5,850,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Catalent in the 2nd quarter worth about $42,000. Sentry Investment Management LLC bought a new position in shares of Catalent in the third quarter valued at approximately $53,000. Longfellow Investment Management Co. LLC increased its position in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after acquiring an additional 305 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares during the period. Finally, Intact Investment Management Inc. purchased a new position in Catalent in the third quarter worth $73,000.

Insider Transactions at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. The trade was a 5.21 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on CTLT shares. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. StockNews.com upgraded shares of Catalent from a “sell” rating to a “hold” rating in a research note on Thursday. Finally, Robert W. Baird restated a “neutral” rating and set a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. Nine research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $59.83.

Catalent Stock Down 0.3 %

CTLT opened at $58.95 on Friday. Catalent, Inc. has a 12 month low of $36.00 and a 12 month high of $61.20. The company has a market cap of $10.70 billion, a PE ratio of -26.07, a price-to-earnings-growth ratio of 2.36 and a beta of 1.16. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The company has a 50 day moving average of $59.89 and a 200 day moving average of $58.16.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.10) earnings per share. On average, sell-side analysts expect that Catalent, Inc. will post 0.84 EPS for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.